Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PillCam SB approved in Japan

This article was originally published in The Gray Sheet

Executive Summary

Given Imaging receives approval in Japan for its PillCam SB endoscopy video capsule for detection of obscure bleeding. The Israeli firm will launch PillCam SB through 28 sales reps from its Japanese joint venture established in 2002 with medical device and pharmaceutical distributor Suzuken and trading company Marubeni (1"The Gray Sheet" Feb. 14, 2005, p. 22). Given expects to receive a reimbursement decision within nine to 12 months. The firm originally expected approval in 2005 but says that its protracted three year process is average for Japan. PillCam SB already is available in the United States and Europe...
Advertisement

Related Content

Given Imaging’s Japan Reimbursement Drives 45% Stock Gain In 2nd Quarter
Given Imaging Eyes Japan, Expanded Reimbursement For PillCam Capsules
Given Imaging Eyes Japan, Expanded Reimbursement For PillCam Capsules
Advertisement
UsernamePublicRestriction

Register

MT024750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel